AVBP
Arrivent·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 2
Stock Price Surged Significantly
Consensus Rating "Strong Buy"
Ample Liquidity
Significant Net Income Decline
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About AVBP
Arrivent Biopharma, Inc.
A clinical-stage biopharmaceutical company
18 Campus Boulevard, Suite 100 Newtown Square, PA 19073
--
Arrivent Biopharma, Inc., was incorporated under the laws of the State of Delaware on April 14, 2021. The company is a clinical-stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated drugs to address the unmet medical needs of cancer patients. The company seeks to leverage the team's deep drug development experience to maximize the potential of its lead development candidate furamotinib through approval and commercialization in patients with cancer, and to advance a range of new therapies, such as next-generation antibody drug conjugates, with an initial focus on solid tumors.
Company Financials
EPS
AVBP has released its 2025 Q3 earnings. EPS was reported at -0.83, versus the expected -0.78, missing expectations. The chart below visualizes how AVBP has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
